Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH17 nanoCAR circular RNA
- Development stage
- Preclinical
- Lead developer
- Citil Pharma
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CDH17 nanoCAR circular RNA is a preclinical-stage in situ chimeric antigen receptor (CAR) therapy developed by Citil Pharma for the treatment of colorectal cancer. The therapeutic utilizes circular RNA (circRNA) to encode a CAR specific for Cadherin-17 (CDH17), a cell surface marker frequently overexpressed in gastrointestinal malignancies. This circRNA is encapsulated within lipid nanoparticles (LNPs) that are targeted using a nanobody against CD11b, a marker found on various myeloid and lymphoid immune subsets. By delivering the genetic instructions directly to immune cells in vivo, the therapy aims to generate CAR-NK or CAR-NKT cells within the patient's body, potentially offering a more accessible and scalable alternative to traditional ex vivo CAR-T cell manufacturing.
- Other names
- CDH17 nanoCARCDH-17 nanoCARCDH 17 nanoCARCD11b Nanobody-Targeted LNP-delivered circular RNACD-11b Nanobody-Targeted LNP-delivered circular RNACD 11b Nanobody-Targeted LNP-delivered circular RNA
02
Targets
αMβ2 (Integrin αMβ2)CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CDH17 nanoCAR circular RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH17 nanoCAR circular RNA.